Renal Cancer - Results from #1700

Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. December 24, 2021

AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease. December 24, 2021

Identification of the Prognostic Value Among Suppressor Of Cytokine Signaling Family Members in Kidney Renal Clear Cell Carcinoma. December 23, 2021

Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients. December 23, 2021

Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. December 22, 2021

2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma. December 22, 2021

Risk models for recurrence and survival after kidney cancer: a systematic review. December 21, 2021

CaboPoint: a Phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma. December 21, 2021

Multimodal Deep Learning for Prognosis Prediction in Renal Cancer. December 20, 2021

Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14). December 20, 2021

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery December 17, 2021

Development and Validation of a Predictive Model to Evaluate the Risk of Bone Metastasis in Kidney Cancer. December 17, 2021

First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. December 17, 2021

Prognostic value of CDCA3 in kidney renal papillary cell carcinoma. December 16, 2021

Integrative Analysis of Immune-Related Genes in the Tumor Microenvironment of Renal Clear Cell Carcinoma and Renal Papillary Cell Carcinoma. December 16, 2021

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. December 15, 2021

Robotic Assisted Caval Replacement for Recurrent Renal Cell Carcinoma Invading the wall of the IVC. December 15, 2021

Combination therapies in clinical trials for renal cell carcinoma: how could they impact future treatments? December 14, 2021

Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I. December 14, 2021

Refractory cytokine release reaction to Nivolumab: Following desensitization algorithms to optimize the management of drug hypersensitivity. December 13, 2021

Page 86 of 456